Director at $CNMD Sells 1,103 Shares in Insider Sale

Charles Farkas, a director at $CNMD, divested 1,103 shares of the company on 09-12-2025, generating an approximate $59,049 revenue. The transaction details were extracted from a recent SEC filing, indicating a sale of roughly 6.5% of this specific class of shares held. After this sale, Farkas retains ownership of 15,756 shares of the same class of $CNMD stock.

Over the past half-year, insiders have engaged in 4 trades involving $CNMD stock on the public market. Of these transactions, none were purchases, while 4 constituted sales. Breaking down insider trading activity on $CNMD stock over the last 6 months reveals that Charles Farkas executed 0 purchases and 3 sales, offloading a total of 6,000 shares for an estimated $334,817. Additionally, Todd W. Garner, the Executive Vice President & CFO, sold 598 shares for a sum of $31,365.

Turning attention to hedge fund activity around $CNMD, 133 institutional investors augmented their $CNMD stock holdings in the most recent quarter, while 176 reduced their positions. Key movements include Deerfield Management Company, L.P. increasing their portfolio by 700,271 shares, valued at $36,470,113 in Q2 2025, and Fuller & Thaler Asset Management, Inc. boosting their holdings by 566,598 shares, equivalent to $29,508,423. On the flip side, ClearBridge Investments, LLC disposed of 542,966 shares in Q1 2025, totaling $32,789,716.

In terms of analyst ratings, Wall Street analysts have issued evaluations on $CNMD in recent months, with 1 firm providing a buy rating and 0 suggesting a sell rating. For instance, Piper Sandler published an “Overweight” assessment on 07/31/2025. Multiple analysts have also set price targets for $CNMD in the last 6 months, with a median target of $58.0. Notable recent price targets include Matt O’Brien from Piper Sandler with a $68.0 target price on 07/31/2025 and Mike Matson from Needham setting a target price of $61.0 on 06/12/2025.

It is important to note that this article does not constitute financial advice. Always refer to Quiver Quantitative’s disclaimers for further details.